Erste Asset Management GmbH Makes New $4.08 Million Investment in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Erste Asset Management GmbH bought a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 500,000 shares of the company's stock, valued at approximately $4,075,000. Erste Asset Management GmbH owned approximately 0.90% of Ginkgo Bioworks as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC acquired a new position in shares of Ginkgo Bioworks during the 2nd quarter worth approximately $3,391,000. Monaco Asset Management SAM acquired a new position in shares of Ginkgo Bioworks during the 2nd quarter worth approximately $3,276,000. Renaissance Technologies LLC acquired a new position in shares of Ginkgo Bioworks during the 2nd quarter worth approximately $2,128,000. Cetera Investment Advisers increased its position in shares of Ginkgo Bioworks by 2,683.7% during the 1st quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company's stock worth $2,626,000 after purchasing an additional 2,182,773 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Ginkgo Bioworks during the 2nd quarter worth approximately $312,000. Institutional investors own 78.63% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on DNA. TD Cowen boosted their price target on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. BTIG Research boosted their target price on Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a report on Friday, August 23rd. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $4.58.

Ginkgo Bioworks Stock Up 1.3 %

DNA stock traded up $0.12 during mid-day trading on Tuesday, hitting $9.74. 1,360,913 shares of the company were exchanged, compared to its average volume of 1,147,505. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $75.20. The business has a 50 day simple moving average of $8.00. The firm has a market cap of $559.57 million, a PE ratio of -0.74 and a beta of 1.17.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.